<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="for the prevention of cytomegalovirus infection, such as acyclovir, valacyclovir," exact="ganciclovir" post="and valganciclovir. Methods We searched relevant prospective and multi-armed"/>
 <result pre="in the analysis. In the case of cytomegalovirus infection, the" exact="ganciclovir" post="group (OR = 0.24, 95% CI 0.09–0.57) and the valacyclovir group"/>
 <result pre="0.04–0.69) provided significantly better outcomes than the control group. The" exact="ganciclovir" post="(OR = 0.37, 95% CI 0.13–0.86) and valacyclovir groups (OR = 0.31, 95%"/>
 <result pre="acyclovir group. As for cytomegalovirus disease, the ganciclovir, valacyclovir and" exact="valganciclovir" post="groups showed significant advantages compared with the control group"/>
 <result pre="OR = 0.17, 95% CI 0.07–0.31, valacyclovir group: OR = 0.08, 95% CI 0.01–0.33," exact="valganciclovir" post="group: OR = 0.14, 95% CI 0.02–0.45). Similarly, the ganciclovir group"/>
 <result pre="CI 0.01–0.33, valganciclovir group: OR = 0.14, 95% CI 0.02–0.45). Similarly, the" exact="ganciclovir" post="group (OR = 0.38, 95% CI 0.12–0.71) and the valacyclovir group"/>
 <result pre="symptoms of CMV infection after solid organ transplantation [7]. Although" exact="ganciclovir" post="and valganciclovir are recommended for CMV treatment according to"/>
 <result pre="CMV infection after solid organ transplantation [7]. Although ganciclovir and" exact="valganciclovir" post="are recommended for CMV treatment according to the third"/>
 <result pre="in use for CMV prevention and treatment, including acyclovir, valacyclovir," exact="ganciclovir" post="and valganciclovir. However, these antiviral drugs are associated with"/>
 <result pre="84 27 3 (11) 168 Cyclosporine, azathioprine, steroids Acyclovir vs" exact="ganciclovir" post="Singh [8] Liver Prophylaxis Acyclovir 3200 7 24 7"/>
 <result pre="Liver Prophylaxis Acyclovir 3200 7 24 7 (30) 168 Tacrolimus," exact="methylprednisolone" post="Preemptive Ganciclovir 10 mg/kg 168 23 8 (33) 168"/>
 <result pre="Preemptive Ganciclovir 10 mg/kg 168 23 8 (33) 168 Tacrolimus," exact="methylprednisolone" post="Duncan [9] Lung Prophylaxis Acyclovir 3200 90 12 742 ± 44"/>
 <result pre="Acyclovir 3200 90 12 742 ± 44 Azathioprine, cyclosporine, antilymphoblast globulin/antilymphocyt globulin," exact="methylprednisolone" post="Prophylaxis Ganciclovir 5 mg/kg 5 days/week 90 13 690 ± 85"/>
 <result pre="5 days/week 90 13 690 ± 85 Azathioprine, cyclosporine, antilymphoblast globulin/antilymphocyt globulin," exact="methylprednisolone" post="Rubin [10] Renal, heart, liver Prophylaxis Acyclovir 1200 84"/>
 <result pre="[11] Liver Prophylaxis Acyclovir 3200 100 109 365 Tacrolimus/cyclosporine, corticosteroids," exact="azathioprine" post="Prophylaxis Ganciclovir 3000 100 110 365 Tacrolimus/cyclosporine, corticosteroids, azathioprine"/>
 <result pre="corticosteroids, azathioprine Prophylaxis Ganciclovir 3000 100 110 365 Tacrolimus/cyclosporine, corticosteroids," exact="azathioprine" post="Acyclovir vs valacyclovir Egan [12] Heart Prophylaxis Acyclovir 800"/>
 <result pre="Prophylaxis Acyclovir 800 90 13 1 (7) 180 Azathioprine, cyclosporine," exact="prednisolone" post="Prophylaxis Valacyclovir 2000 90 14 0 (0) 180 Azathioprine,"/>
 <result pre="Prophylaxis Valacyclovir 2000 90 14 0 (0) 180 Azathioprine, cyclosporine," exact="prednisolone" post="Ganciclovir vs control Merigan [13] Heart Prophylaxis Ganciclovir 10"/>
 <result pre="Preemptive Ganciclovir 2.5 mg/kg/days 9 64 180 Azathioprine, cyclosporine, prednisone," exact="methylprednisolone" post="Preemptive Control 0 0 49 180 Azathioprine, cyclosporine, prednisone,"/>
 <result pre="methylprednisolone Preemptive Control 0 0 49 180 Azathioprine, cyclosporine, prednisone," exact="methylprednisolone" post="Gane [15] Liver Prophylaxis Ganciclovir 3000 98 150 21"/>
 <result pre="Renal Preemptive Ganciclovir 3000 49 42 5 (12) 365 Tacrolimus/cyclosporine," exact="prednisolone" post="Deferred Control 3000 28 38 3 (8) 365 Tacrolimus/cyclosporine,"/>
 <result pre="prednisolone Deferred Control 3000 28 38 3 (8) 365 Tacrolimus/cyclosporine," exact="prednisolone" post="Ganciclovir vs valacyclovir Pavlopoulou [18] Renal Prophylaxis Ganciclovir 3000"/>
 <result pre="Prophylaxis Ganciclovir 3000 90 40 6 (14) 180 Tacrolimus, MMF," exact="methylprednisolone" post="Prophylaxis Valacyclovir 8000 90 43 6 (15) 180 Tacrolimus,"/>
 <result pre="Prophylaxis Valacyclovir 8000 90 43 6 (15) 180 Tacrolimus, MMF," exact="methylprednisolone" post="Reischig [19] Renal Prophylaxis Ganciclovir 3000 90 36 5"/>
 <result pre="Prophylaxis Ganciclovir 3000 90 36 5 (14) 730 Tacrolimus, MMF," exact="azathioprine" post="Prophylaxis Valacyclovir 8000 90 35 4 (11) 730 Tacrolimus,"/>
 <result pre="Prophylaxis Valacyclovir 8000 90 35 4 (11) 730 Tacrolimus, MMF," exact="azathioprine" post="Ganciclovir vs valganciclovir Paya [20] Heart, liver, renal, pancreas"/>
 <result pre="90 35 4 (11) 730 Tacrolimus, MMF, azathioprine Ganciclovir vs" exact="valganciclovir" post="Paya [20] Heart, liver, renal, pancreas Prophylaxis Ganciclovir 3000"/>
 <result pre="outcomes of infection were not shown [11–13] (Fig. 3a). The" exact="ganciclovir" post="group (OR = 0.24, 95% CI 0.09–0.57) and the valacyclovir group"/>
 <result pre="0.04–0.69) performed significantly better than the control group, while the" exact="valganciclovir" post="group (OR = 0.31, 95% CI 0.06–1.49) and the acyclovir group"/>
 <result pre="no significant advantage compared to the control group. Moreover, the" exact="ganciclovir" post="(OR = 0.37, 95% CI 0.13–0.86) and valacyclovir groups (OR = 0.31, 95%"/>
 <result pre="group. However, the comparison between the valacyclovir group and the" exact="ganciclovir" post="group did not show significant differences in their efficacy"/>
 <result pre="we can observe in Fig. 3B, the ganciclovir, valacyclovir and" exact="valganciclovir" post="groups showed significant advantages over the control group (ganciclovir"/>
 <result pre="OR = 0.17, 95% CI 0.07–0.31; valacyclovir group: OR = 0.08, 95% CI 0.01–0.33;" exact="valganciclovir" post="group: OR = 0.14, 95% CI 0.02–0.45). There were still no"/>
 <result pre="and the control group (OR = 0.44, 95% CI 0.19–1.21). Furthermore, the" exact="ganciclovir" post="group results were moderately better than those obtained with"/>
 <result pre="superior to the acyclovir group (OR = 0.17, 95% CI: 0.03-0.72). The" exact="valganciclovir" post="group showed no significant advantages than the acyclovir group"/>
 <result pre="of the 17 studies were included [7, 14–22]. Both the" exact="ganciclovir" post="and valacyclovir groups showed significant advantages compared with the"/>
 <result pre="0.06–0.57; valacyclovir group: OR = 0.27, 95% CI 0.05–0.83). Of note, the" exact="valganciclovir" post="group also showed significant statistical differences compared to the"/>
 <result pre="compared to the control group (OR = 0.22, 95% CI 0.03–0.79). The" exact="ganciclovir" post="group showed better activity compared to the acyclovir group"/>
 <result pre="OR = 0.16, 95% CI 0.04–0.40; valacyclovir group: OR = 0.04, 95% CI 0.00–0.27;" exact="valganciclovir" post="group: OR = 0.15, 95% CI 0.02–0.89), while the acyclovir group"/>
 <result pre="differences (OR = 0.38, 95% CI 0.13–1.33). The results obtained with the" exact="ganciclovir" post="group were superior to those obtained for the acyclovir"/>
 <result pre="S3) showed that there is low-degree heterogeneity except when comparing" exact="valganciclovir" post="and valacyclovir. About the direct pairwise comparisons of CMV"/>
 <result pre="S5B), it was found a high degree of heterogeneity between" exact="valganciclovir" post="and valacyclovir in acute rejection. About the inconsistency analysis,"/>
 <result pre="still be valacyclovir (0.59). The second and third are respectively" exact="ganciclovir" post="(0.44) and valganciclovir (0.49), while the last one is"/>
 <result pre="(0.59). The second and third are respectively ganciclovir (0.44) and" exact="valganciclovir" post="(0.49), while the last one is acyclovir (0.71). As"/>
 <result pre="occurrence of CMV disease after solid organ transplantation, followed by" exact="valganciclovir" post="(0.53), ganciclovir (0.63) and acyclovir (0.92). In terms of"/>
 <result pre="CMV disease after solid organ transplantation, followed by valganciclovir (0.53)," exact="ganciclovir" post="(0.63) and acyclovir (0.92). In terms of acute rejection"/>
 <result pre="Figure S8A), the most probably induction order is acyclovir (0.57)," exact="ganciclovir" post="(0.60), valganciclovir (0.47) and valacyclovir (0.63). Concerning the inducement"/>
 <result pre="the most probably induction order is acyclovir (0.57), ganciclovir (0.60)," exact="valganciclovir" post="(0.47) and valacyclovir (0.63). Concerning the inducement of leukopenia"/>
 <result pre="S8B), the safest antiviral drug was acyclovir (0.92) followed by" exact="ganciclovir" post="(0.44), valacyclovir (0.46) and valganciclovir (0.56). In the subgroup"/>
 <result pre="was acyclovir (0.92) followed by ganciclovir (0.44), valacyclovir (0.46) and" exact="valganciclovir" post="(0.56). In the subgroup analysis of universal prophylaxis, the"/>
 <result pre="(Additional file 1: Figure S8D) is valacyclovir (0.89), followed by" exact="valganciclovir" post="(0.50), ganciclovir (0.54), acyclovir (0.86). It was not possible"/>
 <result pre="1: Figure S8D) is valacyclovir (0.89), followed by valganciclovir (0.50)," exact="ganciclovir" post="(0.54), acyclovir (0.86). It was not possible to assess"/>
 <result pre="downgraded our confidence in the network and for the comparison" exact="ganciclovir" post="versus valacyclovir about CMV disease after solid organ transplantation."/>
 <result pre="for the treatment of CMV infection, such as acyclovir, valacyclovir," exact="ganciclovir" post="and valganciclovir. But there is lack of head-to-head clinical"/>
 <result pre="and resistance effects of the CMV antiviral drugs -acyclovir, valacyclovir," exact="ganciclovir" post="and valganciclovir. 17 studies involving 2062 patients were included"/>
 <result pre="From the results obtained from our network meta-analysis, valacyclovir and" exact="ganciclovir" post="could effectively prevent CMV infection and disease after solid"/>
 <result pre="in the prevention of CMV disease. Although the comparison between" exact="valganciclovir" post="and control groups did not reach statistical significance. The"/>
 <result pre="valganciclovir and control groups did not reach statistical significance. The" exact="valganciclovir" post="group (CMV infection: p = 0.49) showed that it may have"/>
 <result pre="after solid organ transplantation, the preventive effect of valacyclovir and" exact="ganciclovir" post="was significantly better than that of acyclovir. No significant"/>
 <result pre="than that of acyclovir. No significant differences between valacyclovir and" exact="ganciclovir" post="were noted in prevention of CMV infection and disease"/>
 <result pre="after solid organ transplantation. Compared with the control group, valacyclovir," exact="valganciclovir" post="and ganciclovir play an active role in the prevention"/>
 <result pre="organ transplantation. Compared with the control group, valacyclovir, valganciclovir and" exact="ganciclovir" post="play an active role in the prevention of CMV"/>
 <result pre="one. Acyclovir had the lowest probability to induce leukocytopenia and" exact="valganciclovir" post="had the highest probability to induce. Considering the positive"/>
 <result pre="effect, with minimum chance of leukopenia occurrence. Compared to ganciclovir," exact="valganciclovir" post="is the most efficient in controlling CMV disease, but"/>
 <result pre="still likely to be our best choice, followed by valganciclovir," exact="ganciclovir" post="and acyclovir. However, valacyclovir did not show significant advantages"/>
 <result pre="acyclovir. However, valacyclovir did not show significant advantages compared to" exact="valganciclovir" post="and ganciclovir for the treatment of CMV infection. There"/>
 <result pre="valacyclovir did not show significant advantages compared to valganciclovir and" exact="ganciclovir" post="for the treatment of CMV infection. There are several"/>
 <result pre="highdegree: &amp;gt; 75%). There is a high-degree heterogeneity between the comparison between" exact="valganciclovir" post="and valacyclovir. Figure S4. Direct pairwise comparisons of CMV"/>
 <result pre="rejection, There is a low-degree heterogeneity between the comparison between" exact="ganciclovir" post="and valacyclovir and a high-degree heterogeneity between the comparison"/>
 <result pre="and valacyclovir and a high-degree heterogeneity between the comparison between" exact="valganciclovir" post="and valacyclovir. As for leukopenia, There is only a"/>
 <result pre="al.Multicenter evaluation of efficacy and safety of low-dose versus high-dose" exact="valganciclovir" post="for prevention of cytomegalovirus disease in donor and recipient"/>
 <result pre="renal transplant recipientsTransplant Infect Dis2016186904912 7.PayaCHumarADominguezEet al.Efficacy and safety of" exact="valganciclovir" post="vs. oral ganciclovir for prevention of cytomegalovirus disease in"/>
 <result pre="Infect Dis2016186904912 7.PayaCHumarADominguezEet al.Efficacy and safety of valganciclovir vs. oral" exact="ganciclovir" post="for prevention of cytomegalovirus disease in solid organ transplant"/>
 <result pre="networks of interventionsInt J Epidemiol201342133234523508418 11.MeriganTCRenlundDGKeaySet al.A controlled trial of" exact="ganciclovir" post="to prevent cytomegalovirus disease after heart transplantationN Engl J"/>
 <result pre="randomized, comparative studyNephrol Dialysis Transplant200318918991908 13.WinstonDJBusuttilRWRandomized controlled trial of oral" exact="ganciclovir" post="versus oral acyclovir after induction with intravenous ganciclovir for"/>
 <result pre="of oral ganciclovir versus oral acyclovir after induction with intravenous" exact="ganciclovir" post="for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver"/>
 <result pre="in liver transplant patientsTransplant Infect Dis1999128997 16.DuncanSRGrgurichWFIaconoATet al.A comparison of" exact="ganciclovir" post="and acyclovir to prevent cytomegalovirus after lung transplantationAm J"/>
 <result pre="Med199415011461528025741 17.GaneESalibaFValdecasasGJet al.Randomised trial of efficacy and safety of oral" exact="ganciclovir" post="in the prevention of cytomegalovirus disease in liver-transplant recipients."/>
 <result pre="of primary cytomegalovirus disease in organ transplant recipients with oral" exact="ganciclovir" post="or oral acyclovir prophylaxisTransplant Infect Dis200023112117 19.PavlopoulouIDSyriopoulouVPCheliotiHet al.A comparative"/>
 <result pre="Dis200023112117 19.PavlopoulouIDSyriopoulouVPCheliotiHet al.A comparative randomised study of valacyclovir vs. oral" exact="ganciclovir" post="for cytomegalovirus prophylaxis in renal transplant recipientsClin Microbiol Infect200511973674316104989"/>
 <result pre="the risk of acute renal allograft rejectionTransplantation200579331732415699762 22.ReischigTKacerMJindraPHesOLysakDBoudaMRandomized trial of" exact="valganciclovir" post="versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal"/>
 <result pre="Am Soc Nephrol CJASN201510229430425424991 23.SinghNYuVLMielesLWagenerMMMinerRCGayowskiTHigh-dose acyclovir compared with short-course preemptive" exact="ganciclovir" post="therapy to prevent cytomegalovirus disease in liver transplant recipients."/>
 <result pre="liver transplant recipients. A randomized trialAnn internal Med199412053753818304654 24.HibberdPLTolkoff-RubinNEContiDet al.Preemptive" exact="ganciclovir" post="therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal"/>
 <result pre="randomized controlled trialAnn Internal Med1995123118267762909 25.PayaCVWilsonJAEspyMJet al.Preemptive use of oral" exact="ganciclovir" post="to prevent cytomegalovirus infection in liver transplant patients: a"/>
 <result pre="randomized, placebo-controlled trialJ Infect Dis2002185785486011920308 26.ReischigTHribovaPJindraPet al.Long-term outcomes of pre-emptive" exact="valganciclovir" post="compared with valacyclovir prophylaxis for prevention of cytomegalovirus in"/>
</results>
